查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574220

克隆氏症藥物市場：按藥物類別、給藥途徑、分銷管道、年齡層分類 - 全球預測 2025-2030

Crohn's Disease Therapeutics Market by Therapeutics Class (Biologics, Conventional Drugs), Route Of Administration (Oral, Parenteral), Distribution Channel, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

克隆氏症治療藥物市場2023年估值為127.6億美元，預計到2024年將達到133.6億美元，複合年成長率為5.47%，預計到2030年將達到185.4億美元。

克隆氏症藥物的範圍和定義包括各種旨在控制症狀、誘導和維持緩解以及改善這種慢性發炎性腸道疾病患者的生活品質的治療方法。由於克隆氏症，需要這些治療，這種疾病會導致腹痛、嚴重腹瀉、疲勞和營養不良等衰弱症狀。治療應用範圍從發炎藥物和免疫抑制劑到生技藥品和新的個人化醫療方法。最終用途範圍主要是醫療保健環境，例如醫院、專科診所和專注於胃腸道疾病的研究機構。影響市場成長的關鍵因素包括生物製藥治療的進步、克隆氏症全球盛行率的增加以及患者和醫療保健專業人員對新治療方案的認知不斷提高。然而，他們面臨著治療成本上升、潛在副作用以及患者對治療反應不同等挑戰。最新的潛在治療機會來自腸道微生物組治療和個人化醫療的持續研究，提供有針對性的有效治療方法。建議的治療方法包括投資新治療方法的研發、利用資料分析制定個人化治療計劃以及建立策略夥伴關係以擴大市場。監管障礙和生物相似藥的競爭壓力等限制仍然是主要挑戰。最佳創新領域是生物相似藥的開發、預測診斷基因研究的進展以及使用數位健康技術進行患者監測和參與。該市場的特點是技術快速進步，但必須謹慎管理監管環境和成本管理，以確保永續成長。透過專注於雲端基礎的研究合作和以患者為中心的護理模式，公司可以對自己進行策略性定位，以利用市場的動態特性。

主要市場統計
基準年[2023] 127.6億美元
預測年份 [2024] 133.6億美元
預測年份 [2030] 185.4億美元
複合年成長率（%） 5.47%

市場動態：揭示快速發展的克隆氏症症藥物市場的關鍵市場洞察

克隆氏症藥物市場正在因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 由於患者預後改善，對克隆氏症標靶治療的需求增加
    • 擴大發展中地區克隆氏症治療的醫療基礎設施和可近性
    • 支持克隆氏症研究和開發新藥的政府措施和資金
    • 生物創業公司與研究機構聯合研究開發新藥
  • 市場限制因素
    • 嚴格的監管要求推遲了克隆氏症病藥物的核准
    • 缺乏可靠的臨床試驗資料削弱了人們對克隆氏症藥物的信心
  • 市場機會
    • 開發永續且具成本效益的生物製藥，用於克隆氏症的長期管理
    • 探索腸道菌叢調整療法在克隆氏症治療的潛力
    • 擴大精準醫學的使用，以確定個別患者對克隆氏症治療的反應
  • 市場挑戰
    • 解決患者對克隆氏症治療方法的依從性和長期承諾
    • 解決與先進克隆氏症治療相關的高成本和保險障礙

波特五力：駕馭克隆氏症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解克隆氏症藥物市場的外部影響

外部宏觀環境因素在塑造克隆氏症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解克隆氏症治療藥物市場的競爭狀況

對克隆氏症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣克隆氏症治療市場供應商的績效評估

FPNV 定位矩陣是評估克隆氏症治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃克隆氏症治療藥物市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對克隆氏症治療藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 患者治療效果的改善推動了克隆氏症標靶治療的需求
      • 擴大發展中地區克隆氏症治療的醫療基礎設施和可近性
      • 支持克隆氏症研究和開發新藥的政府措施和資金
      • 生技公司與研究機構合作開發新的克隆氏症治療方法
    • 抑制因素
      • 嚴格的監管要求推遲了克隆氏症新療法的核准
      • 缺乏可靠的臨床試驗資料降低了人們對克隆氏症藥物的信心
    • 機會
      • 開發永續且具有成本效益的生物治療方法來長期管理克隆氏症
      • 探索腸道微生物群調節療法治療克隆氏症的潛力
      • 擴大精準醫學的使用以確定個別患者對克隆氏症治療的反應
    • 任務
      • 解決患者對克隆氏症治療方法的依從性和長期承諾
      • 管理與晚期克隆氏症治療相關的高成本和保險障礙
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療層級的克隆氏症治療藥物市場

  • 生物製藥
    • 抗整合素治療
    • 白細胞介素抑制劑
    • 單株抗體
  • 傳統醫學
    • 氨基胺基
    • 皮質類固醇
    • 免疫抑制劑

第7章克隆氏症治療藥物市場：依給藥途徑

  • 口服
    • 膠囊
    • 藥片
  • 胃腸外的
    • 注射

第8章克隆氏症治療藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第9章克隆氏症治療藥物市場：依年齡層

  • 成人
  • 小兒科

第10章美洲克隆氏症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太克隆氏症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲克隆氏症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064C0471

The Crohn's Disease Therapeutics Market was valued at USD 12.76 billion in 2023, expected to reach USD 13.36 billion in 2024, and is projected to grow at a CAGR of 5.47%, to USD 18.54 billion by 2030.

The scope and definition of Crohn's Disease Therapeutics encompass the various treatments aimed at managing symptoms, inducing and maintaining remission, and improving the quality of life for patients suffering from this chronic inflammatory bowel disease. The necessity for these therapeutics is driven by the complex nature of Crohn's Disease, which can lead to debilitating symptoms such as abdominal pain, severe diarrhea, fatigue, and malnutrition. The application of therapeutics ranges from anti-inflammatory drugs and immunosuppressants to biologics and emerging personalized medicine approaches. End-use scope is primarily in healthcare settings such as hospitals, specialist clinics, and research institutions focusing on gastrointestinal disorders. Key factors influencing market growth include advancements in biologic therapies, increasing prevalence of Crohn's Disease globally, and rising awareness among patients and healthcare providers about new treatment options. However, the market faces challenges due to high treatment costs, potential side effects, and varying patient responses to therapies. Latest potential opportunities arise from ongoing research in gut microbiome therapies and personalized medicine, offering targeted and efficient treatment practices. Recommendations include investing in R&D for novel therapies, leveraging data analytics for personalized treatment plans, and engaging in strategic partnerships to expand market reach. Limitations such as regulatory hurdles and competitive pressure from biosimilars remain significant challenges. The best areas of innovation lie in the development of biosimilars, advancements in genetic studies for predictive diagnostics, and leveraging digital health technologies for patient monitoring and engagement. The market is characterized by rapid technological advancements but requires careful navigation through regulatory landscapes and cost management to ensure sustainable growth. By focusing on cloud-based research collaborations and patient-centric care models, businesses can strategically position themselves to leverage the dynamic nature of the Crohn's Disease Therapeutics market.

KEY MARKET STATISTICS
Base Year [2023] USD 12.76 billion
Estimated Year [2024] USD 13.36 billion
Forecast Year [2030] USD 18.54 billion
CAGR (%) 5.47%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Crohn's Disease Therapeutics Market

The Crohn's Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing demand for targeted Crohn's disease treatments due to better patient outcomes
    • Expanded healthcare infrastructure and accessibility in developing regions for Crohn's disease treatment
    • Government initiatives and funding to support Crohn's disease research and new drug development
    • Collaborations between biotech firms and research institutions for novel Crohn's disease therapeutics
  • Market Restraints
    • Stringent regulatory requirements slow down the approval of new Crohn's disease treatments
    • Lack of robust clinical trial data diminishes confidence in Crohn's disease therapeutics
  • Market Opportunities
    • Developing sustainable and cost-effective biologic therapies for long-term management of Crohn's disease
    • Exploring the potential of gut microbiome modulation therapies in the treatment of Crohn's disease
    • Expanding the use of precision medicine in identifying individual patient response to Crohn's disease treatments
  • Market Challenges
    • Addressing patient adherence and long-term commitment to Crohn's disease therapeutic regimens
    • Managing high costs and insurance barriers associated with advanced Crohn's disease treatments

Porter's Five Forces: A Strategic Tool for Navigating the Crohn's Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Crohn's Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Crohn's Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Crohn's Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Crohn's Disease Therapeutics Market

A detailed market share analysis in the Crohn's Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Crohn's Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Crohn's Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Crohn's Disease Therapeutics Market

A strategic analysis of the Crohn's Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Crohn's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences Inc., Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Nestle Health Science, Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Crohn's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutics Class, market is studied across Biologics and Conventional Drugs. The Biologics is further studied across Anti-Integrin Therapy, Interleukin Inhibitors, and Monoclonal Antibodies. The Conventional Drugs is further studied across Aminosalicylates, Corticosteroids, and Immunosuppressants.
  • Based on Route Of Administration, market is studied across Oral and Parenteral. The Oral is further studied across Capsules and Tablets. The Parenteral is further studied across Injectables.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Age Group, market is studied across Adults and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for targeted Crohn's disease treatments due to better patient outcomes
      • 5.1.1.2. Expanded healthcare infrastructure and accessibility in developing regions for Crohn's disease treatment
      • 5.1.1.3. Government initiatives and funding to support Crohn's disease research and new drug development
      • 5.1.1.4. Collaborations between biotech firms and research institutions for novel Crohn's disease therapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent regulatory requirements slow down the approval of new Crohn's disease treatments
      • 5.1.2.2. Lack of robust clinical trial data diminishes confidence in Crohn's disease therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing sustainable and cost-effective biologic therapies for long-term management of Crohn's disease
      • 5.1.3.2. Exploring the potential of gut microbiome modulation therapies in the treatment of Crohn's disease
      • 5.1.3.3. Expanding the use of precision medicine in identifying individual patient response to Crohn's disease treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Addressing patient adherence and long-term commitment to Crohn's disease therapeutic regimens
      • 5.1.4.2. Managing high costs and insurance barriers associated with advanced Crohn's disease treatments
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Crohn's Disease Therapeutics Market, by Therapeutics Class

  • 6.1. Introduction
  • 6.2. Biologics
    • 6.2.1. Anti-Integrin Therapy
    • 6.2.2. Interleukin Inhibitors
    • 6.2.3. Monoclonal Antibodies
  • 6.3. Conventional Drugs
    • 6.3.1. Aminosalicylates
    • 6.3.2. Corticosteroids
    • 6.3.3. Immunosuppressants

7. Crohn's Disease Therapeutics Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Oral
    • 7.2.1. Capsules
    • 7.2.2. Tablets
  • 7.3. Parenteral
    • 7.3.1. Injectables

8. Crohn's Disease Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacies
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Crohn's Disease Therapeutics Market, by Age Group

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatric

10. Americas Crohn's Disease Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Crohn's Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Crohn's Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Biogen Inc.
  • 4. Bristol-Myers Squibb Company
  • 5. Celgene Corporation
  • 6. Eli Lilly and Company
  • 7. Ferring Pharmaceuticals Inc.
  • 8. Gilead Sciences Inc.
  • 9. Ipsen Biopharmaceuticals, Inc.
  • 10. Johnson & Johnson
  • 11. Merck & Co., Inc.
  • 12. Nestle Health Science
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi S.A.
  • 17. Shire plc.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. CROHN'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CROHN'S DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-INTEGRIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 154. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 169. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 170. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 175. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 177. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 178. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 182. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 183. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 185. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 186. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 197. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 198. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 199. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 202. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 203. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 204. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 205. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 206. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 207. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 208. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 210. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 211. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 214. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 215. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 216. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 218. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 219. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 221. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 223. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 226. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 227. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 229. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 231. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 232. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 234. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 235. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 238. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 239. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 240. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 241. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 242. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 243. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 245. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 246. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 247. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 250. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 251. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 252. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 253. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 254. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 255. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 256. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 258. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 259. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 262. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 263. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 264. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 266. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 267. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 269. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 270. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 271. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 273. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 274. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 275. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 276. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 277. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 278. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 279. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 280. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 282. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 283. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 286. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 287. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 288. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 289. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 290. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 291. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 293. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 294. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 295. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 296. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 298. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 299. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 300. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 301. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 302. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 303. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 304. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 305. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 306. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 308. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 309. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
  • TABLE 310. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 311. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
  • TABLE 312. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 313. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 314.